TD Asset Management Inc Sells 46,673 Shares of Hologic, Inc. (NASDAQ:HOLX)

Key Points

• TD Asset Management Inc reduced its stake in Hologic, Inc. by 3.0% during the first quarter, selling 46,673 shares, leaving it with approximately 1.51 million shares valued at $93.23 million.
• Hologic last reported earnings of $1.03 per share, slightly exceeding estimates, and generated $1.01 billion in revenue, though down 1.2% compared to the previous year.
• Several institutional investors have altered their positions in Hologic, with notable changes including Bank Julius Baer acquiring a new stake worth about $42,000 in the first quarter.

TD Asset Management Inc decreased its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,509,312 shares of the medical equipment provider's stock after selling 46,673 shares during the quarter. TD Asset Management Inc owned approximately 0.67% of Hologic worth $93,230,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Hologic during the first quarter valued at about $42,000. Raiffeisen Bank International AG bought a new stake in Hologic during the fourth quarter valued at about $49,000. Allworth Financial LP boosted its position in Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after purchasing an additional 216 shares in the last quarter. Larson Financial Group LLC boosted its position in Hologic by 6,016.7% during the first quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 722 shares in the last quarter. Finally, West Financial Advisors LLC bought a new stake in Hologic during the first quarter valued at about $50,000. Institutional investors own 94.73% of the company's stock.

Hologic Trading Up 0.6%

Shares of NASDAQ:HOLX opened at $66.50 on Friday. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.67. The stock has a market cap of $14.82 billion, a price-to-earnings ratio of 28.06, a PEG ratio of 2.44 and a beta of 0.55. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. The business has a 50-day moving average price of $63.33 and a 200-day moving average price of $62.93.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The firm had revenue of $1.01 billion during the quarter, compared to analysts' expectations of $1 billion. During the same period last year, the business posted $1.03 earnings per share. The company's revenue for the quarter was down 1.2% compared to the same quarter last year. Equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analyst Ratings Changes

HOLX has been the topic of a number of recent research reports. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and raised their price objective for the company from $60.00 to $80.00 in a research report on Wednesday, July 9th. Raymond James Financial reaffirmed an "outperform" rating and set a $71.00 price objective (down previously from $90.00) on shares of Hologic in a research report on Friday, May 2nd. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a research report on Tuesday, May 27th. Mizuho increased their price target on Hologic from $65.00 to $70.00 and gave the company an "outperform" rating in a research note on Wednesday, July 16th. Finally, Royal Bank Of Canada decreased their price target on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research note on Friday, May 2nd. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $77.33.

Insider Activity

In other news, Director Martin D. Madaus acquired 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The stock was purchased at an average cost of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the purchase, the director directly owned 5,445 shares in the company, valued at $300,781.80. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.88% of the stock is currently owned by insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.